Showing results (11-20 of 335) with videos related to
Sort By:
Pageof 34
Drugs|March 14, 2024
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?Sanne M Buijs, Stijn L W Koolen, Ron H J Mathijssen, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 18, 2024
New metabolic insights into the mechanism of ifosfamide encephalopathyDiren Beyoğlu, Paul Hamberg, Nikki S IJzerman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variabilityFloris A de Jong, Ron H J Mathijssen, Rujia Xie, et al.Journal of the National Cancer Institute|August 22, 2002
Effects of St. John's wort on irinotecan metabolismRon H J Mathijssen, Jaap Verweij, Peter de Bruijn, et al.Pharmacogenomics|July 7, 2010
Pharmacogenetics of tomorrow: the 1 + 1 = 3 principleJan Pander, Judith A M Wessels, Ron H J Mathijssen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Modulation of irinotecan metabolism by ketoconazoleDiederik F S Kehrer, Ron H J Mathijssen, Jaap Verweij, et al.Cancer Letters|December 14, 2005
Role of pharmacogenetics in irinotecan therapyFloris A de Jong, Maja J A de Jonge, Jaap Verweij, et al.Drugs|February 12, 2025
From Prospective Evaluation to Practice: Model-Informed Dose Optimization in OncologyBram C Agema, Birgit C P Koch, Ron H J Mathijssen, et al.European Journal of Clinical Pharmacology|June 9, 2019
Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicineStefanie L Groenland, Ron H J Mathijssen, Jos H Beijnen, et al.The Lancet. Oncology|July 4, 2014
Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspectiveRoelof W F van Leeuwen, Teun van Gelder, Ron H J Mathijssen, et al.Pageof 34